Front-line treatment for advanced non-small-cell lung cancer and ALK fusion: a network meta-analysis

BACKGROUND: It remains unknown what is the optimal front-line choice for advanced non-small-cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) fusion. METHODS: We conducted a systematic review and network meta-analysis of randomized phase III clinical trials comparing two or more treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Wen, Yaokai, Jiang, Tao, Wu, Xiangrong, Peng, Haoxin, Ren, Shengxiang, Zhou, Caicun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403455/
https://www.ncbi.nlm.nih.gov/pubmed/36032351
http://dx.doi.org/10.1177/17588359221116607

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403455/
https://www.ncbi.nlm.nih.gov/pubmed/36032351
http://dx.doi.org/10.1177/17588359221116607

Ejemplares similares